"migalastat" meaning in All languages combined

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "",
        "3": "-stat",
        "t2": "enzyme inhibitor"
      },
      "expansion": "[Term?] + -stat (“enzyme inhibitor”)",
      "name": "af"
    }
  ],
  "etymology_text": "From [Term?] + -stat (“enzyme inhibitor”).",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "migalastat (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "English terms suffixed with -stat",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "topical",
          "langcode": "en",
          "name": "Pharmaceutical drugs",
          "orig": "en:Pharmaceutical drugs",
          "parents": [
            "Drugs",
            "Matter",
            "Pharmacology",
            "Chemistry",
            "Nature",
            "Biochemistry",
            "Medicine",
            "Sciences",
            "All topics",
            "Biology",
            "Fundamental"
          ],
          "source": "w"
        }
      ],
      "examples": [
        {
          "ref": "2015 August 8, “Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase”, in PLOS ONE, →DOI",
          "text": "Based on preclinical data, migalastat HCl in combination with agalsidase is expected to result in the pharmacokinetic (PK) enhancement of agalsidase in plasma by increasing the systemic exposure of active agalsidase, thereby leading to increased cellular levels in disease-relevant tissues.",
          "type": "quotation"
        }
      ],
      "glosses": [
        "A drug used to treat Fabry disease"
      ],
      "id": "en-migalastat-en-noun-W~u9UNfc",
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "drug",
          "drug"
        ],
        [
          "Fabry disease",
          "Fabry disease"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A drug used to treat Fabry disease"
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ]
    }
  ],
  "word": "migalastat"
}

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "",
        "3": "-stat",
        "t2": "enzyme inhibitor"
      },
      "expansion": "[Term?] + -stat (“enzyme inhibitor”)",
      "name": "af"
    }
  ],
  "etymology_text": "From [Term?] + -stat (“enzyme inhibitor”).",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "migalastat (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        "English entries with incorrect language header",
        "English lemmas",
        "English nouns",
        "English term requests",
        "English terms suffixed with -stat",
        "English terms with quotations",
        "English uncountable nouns",
        "en:Pharmaceutical drugs"
      ],
      "examples": [
        {
          "ref": "2015 August 8, “Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase”, in PLOS ONE, →DOI",
          "text": "Based on preclinical data, migalastat HCl in combination with agalsidase is expected to result in the pharmacokinetic (PK) enhancement of agalsidase in plasma by increasing the systemic exposure of active agalsidase, thereby leading to increased cellular levels in disease-relevant tissues.",
          "type": "quotation"
        }
      ],
      "glosses": [
        "A drug used to treat Fabry disease"
      ],
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "drug",
          "drug"
        ],
        [
          "Fabry disease",
          "Fabry disease"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A drug used to treat Fabry disease"
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ]
    }
  ],
  "word": "migalastat"
}